+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Ibuprofen API Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 110 Pages
  • January 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 5026021

The Ibuprofen API market studied is anticipated to grow with a CAGR of nearly 4.8%, during the forecast period.

Certain factors that are driving the market growth include upsurge in pharmaceutical and biopharmaceutical production and growing prevalence of chronic disorders.

The diverse range of diseases, primarily cardiovascular disease, infectious diseases, diabetes, and kidney-related complications, has a high prevalence, globally. Thus, the increasing prevalence of a diverse range of diseases among all age groups and its burden, globally, drives the demand for drug development and its market.

There has been an upsurge in the usage of advanced technologies, such as high throughput, bioinformatics and combinatorial chemistry for better drug candidate identification. Drug discovery has evolved significantly with emerging technologies, helping the process to become more refined, accurate, and less time consuming. Due to automation, multi-detector readers, imaging hardware and software, high-throughput screening is one of the most widely used drug discovery technologies.

Key Market Trends

Arthritis Holds Significant Share in the Global Ibuprofen API Market

Arthritis refers to the inflammation of a joint. When joints are inflamed they can develop stiffness, warmth, swelling, redness and pain. There are over 100 types of arthritis, namely osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, lupus, gout, pseudogout, etc. Rheumatoid arthritis is an autoimmune disorder that causes pain and inflammation in the joints of the body. Rheumatoid arthritis disease mostly affects the joints of the hand, wrists, elbows, knees, and ankles.

Higher doses of ibuprofen are available on prescription and can be used if one has rheumatoid arthritis or another type of inflammatory arthritis. In doses of 1,200 mg/day or more, ibuprofen is as effective as aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of rheumatoid arthritis. The tolerability and safety of ibuprofen are superior to those of aspirin and compare favorably with those of other NSAIDs.

Asia-Pacific is expected to Witness High Growth Rate the Global Ibuprofen API Market

The Asia-Pacific market is anticipated to witness high growth during the forecast period, due to increasing healthcare expenditure. Additionally, the low cost of manufacturing in China and India has resulted in the rise in the production facilities, attracting pharmaceutical and biotechnological giants to the Asia-Pacific region from across the world.

The increase in the incidence of rheumatoid arthritis disease is also expected to propel the market in the region during the forecast period. For example, according to the Institute for Health Metrics and Evaluation, the number of cases of rheumatoid arthritis has increased from 183,272 in 2007 to 263,365 in 2017 in India. Therefore, analyzing the number of cases in other major countries of the Asia Pacific region, the healthcare activities in relation to the treatment of rheumatoid arthritis would require large and continuous support from everyone.

Competitive Landscape

The Ibuprofen API market is competitive and consists of a few major players. Companies like BASF SE, BIOCAUSE Inc., IOL Chemicals And Pharmaceuticals Limited, SI Group, Inc., Sino-US Zibo Xinhua-Perrigo Pharmaceutical Co., Ltd., Solara Active Pharma Sciences Limited., among others, hold the substantial market share in the market.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Upsurge in Pharmaceutical and Biopharmaceutical Production
4.2.2 Growing Prevalence of Chronic Disorders
4.3 Market Restraints
4.3.1 Rising Production Costs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Application
5.1.1 Headache
5.1.2 Arthritis
5.1.3 Others
5.2 By End-User
5.2.1 CROs and CMOs
5.2.2 Pharmaceutical and Biopharmaceutical Company
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 BASF SE
6.1.2 BIOCAUSE Inc.
6.1.3 IOL Chemicals And Pharmaceuticals Limited
6.1.4 SI Group, Inc.
6.1.5 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Co., Ltd.
6.1.6 Solara Active Pharma Sciences Limited

Companies Mentioned

A selection of companies mentioned in this report includes:

  • IOL Chemicals And Pharmaceuticals Limited
  • SI Group, Inc.
  • Sino-US Zibo Xinhua-Perrigo Pharmaceutical Co., Ltd.
  • Solara Active Pharma Sciences Limited